ClinicalTrials.gg
RecruitingNCT07305688Anx-RSUpdated Jun 4, 2026

Climate Anxiety in a Young Population at Risk of Suicide

An observational study in Anxiety, Suicidal Ideation and Mental Health Issue, sponsored by Centre Hospitalier Esquirol. Recruiting at 1 site in France. Open to participants aged 16 Years to 24 Years. Per ClinicalTrials.gov, last updated 2026-06-04.

Primary conditionSuicidal IdeationRegistry: Anxiety DisordersReclassifiedWhy we changed it
Registry
Anxiety Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Suicidal Ideation
Why
  1. The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Suicidal Ideation.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Centre Hospitalier Esquirol · Observational

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
108
Ages
16 Years to 24 Years
Sex
All
01

Study summary

Climate change has become a major source of concern, particularly among younger generations who are facing the progressive degradation of ecosystems, loss of biodiversity, and alarming environmental information disseminated through the media. The direct perception of climate-related disruptions has been shown to engender a profound sense of helplessness and loss. This distress, termed eco-anxiety, is characterised by feelings of fear, sadness and guilt regarding the planet's future.

In a context where there has been a marked increase in suicidal thoughts and attempts among young people over the past decade, it is essential to explore the psychological manifestations of eco-anxiety within this vulnerable population. The paucity of studies investigating this association underscores the significance of the present research.

The aims of this study is to examine the relationship between climate anxiety and suicidal risk among young people aged 16 to 24 years.

The study will encompass 108 young participants aged between 16 and 24 years, who are either hospitalised or receiving outpatient psychiatric care.

Each participant will be required to complete one clinician-administered assessment, namely the Columbia Suicide Severity Rating Scale (C-SSRS), and two self-report questionnaires: the Climate Change Anxiety Scale - French version (CCAS-FR) and the State-Trait Anxiety Inventory (STAI-Y).

Furthermore, a sociodemographic questionnaire will be administered in order to collect information regarding the subjects' age, sex, education level, living conditions, and psychiatric history.

It is hypothesised that there is a positive association between climate anxiety and suicidal risk, with the most eco-anxious participants showing higher C-SSRS scores. It is further predicted that eco-anxiety will correlate with elevated levels of state and trait anxiety, with the potential for modulating this relationship by sociodemographic factors, including gender.

This study will contribute to a better understanding of the psychological impacts of climate change on young people and help identify the most vulnerable profiles.

Read the detailed description

The Anx-RS France study investigates the association between climate change-related anxiety (eco-anxiety) and suicidal ideation among young people aged 16 to 24 years in France. Growing evidence suggests that climate change may contribute to psychological distress and feelings of hopelessness in younger generations. However, data on the link between eco-anxiety and suicide risk in this age group remain limited.

This is an observational, cross-sectional study including 108 participants recruited from university settings and the general population in France. Eligible participants are aged 16-24 years, fluent in French, and provide informed consent (parental consent is obtained for minors). Participants will be excluded if they have a health condition that prevents them from understanding or completing the study questionnaires. This includes major sensory impairments (e.g., deafness, blindness), severe psychiatric disorders affecting cognition or communication (e.g., acute psychosis, pervasive developmental disorder, confusional state), or current hospitalization in specialized psychiatric units for severe mental illness.

Participants complete a self-administered online survey composed of three validated instruments:

  • Climate Change Anxiety Scale (CCAS) - measuring anxiety, rumination, and functional impairment related to climate change.
  • State-Trait Anxiety Inventory (STAI-T/Y) - assessing general trait anxiety levels.
  • Columbia Suicide Severity Rating Scale (C-SSRS) - evaluating suicidal ideation and behavior.

Descriptive analyses will estimate the prevalence and intensity of climate-related anxiety. Correlational and multivariate analyses will assess the association between eco-anxiety (CCAS) and suicidal ideation (C-SSRS), adjusting for general anxiety levels (STAI-T/Y).

The results will improve understanding of how climate-related distress affects mental health and suicide risk among young people in France, and support prevention strategies and mental-health policy adaptation to emerging environmental stressors.

02

Conditions studied

  • Anxiety
  • Suicidal Ideation
  • Mental Health Issue
  • Environmental Exposure

Browse trials for

Keywords

  • Eco-anxiety
  • Anxiety disorders
  • Suicide risk
  • Mental health
  • Young adults
03

In context

Suicidal Ideation Reclassified

569 studies on the registry are indexed under Suicidal Ideation; 203 are open to participants now.

This study's planned enrollment of 108 is below the median of 143 across 74 observational studies indexed under Suicidal Ideation.

Browse Suicidal Ideation studies →

Lead sponsor

Centre Hospitalier Esquirol is the lead sponsor of 25 studies on the registry; 7 are open to participants now.

Compared within Suicidal Ideation, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
16 Years to 24 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

The study population consists of 108 adolescents and young adults aged 16 to 24 years, recruited within the Esquirol Hospital Center (France). Participants are approached in adult and pediatric emergency departments, adult psychiatry, and child and adolescent psychiatry units, as well as during outpatient consultations.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women, boys and girls ;
  • Aged between 16 and 24;
  • Participants seen in adult or pediatric emergency departments, hospitalised in adult psychiatry or in child and adolescent psychiatry, or seen in outpatient consultation at Esquirol Hospital Center ;
  • Affiliated with a social security scheme or entitled to coverage under one ;
  • Having received full information about the study and having co-signed, together with the investigator, an form to participate in the study.
  • For minor participants: the consent to participate in the study must be signed by the holder(s) of parental authority, and the minor's assent will also be required.

Exclusion criteria

Exclusion Criteria:

  • Participants will not be included in the study if their health condition is incompatible with understanding or completing the questionnaires used. This includes, in particular ;
  • Any chronic somatic pathology or major sensory impairment (for example : deafness or blindness) preventing reading, comprehension or communication with healthcare professionals ;
  • Any severe psychiatric pathology that significantly impairs cognitive or communication abilities, such as acute psychotic disorders, pervasive developmental disorders or confusional states ;
  • Participants hospitalised in units specialising in severe psychiatric disorders with major impairment of cognitive functions.
  • Adults under legal protection, in accordance with article L 1121-8 of the Public Health Code ;
  • Insufficient command of the French language
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
108 participants (estimated)
Patient registry
No

Groups and cohorts

  • Young Population at Suicide Risk

    Adolescents and young adults aged 16-24 years, recruited from emergency, inpatient, and outpatient psychiatry units at Esquirol Hospital Center (France). Participants complete standardized questionnaires assessing climate change anxiety (CCAS-FR), suicidal ideation and behavior (C-SSRS), and general anxiety (STAI-C or STAI-Y).

    Other: Columbia Suicide Severity Rating Scale · Other: Climate Change Anxiety Scale - French version · Other: State-Trait Anxiety Inventory, French version · Other: Socio demographic profil

Interventions

  • OtherColumbia Suicide Severity Rating Scale

    Standardized tool for evaluating suicidal ideation and behavior. Measures severity and intensity of suicidal thoughts and actions.

  • OtherClimate Change Anxiety Scale - French version

    22-item self-report questionnaire assessing cognitive, emotional, functional, and pro-environmental dimensions of climate change-related anxiety.

  • OtherState-Trait Anxiety Inventory, French version

    40-item self-report inventory measuring both state and trait anxiety levels.

  • OtherSocio demographic profil

    Collects demographic and background variables such as age, gender, education level and living conditions.

06

What researchers measure

Primary outcomes

  1. Climate Change Anxiety Score

    Global score from the 13-item French version of the Climate Change Anxiety Scale (CCAS-FR), obtained by summing the cognitive, emotional, and functional disturbance subscales. Higher scores indicate greater levels of climate change-related anxiety. Score ranges 13 to 65

    Time frame: 10 min

  2. Suicide Risk Score

    Overall score of suicidal ideation and behavior assessed using the Columbia Suicide Severity Rating Scale (C-SSRS). Higher scores indicate greater suicide risk Score ranges from 2 to 25.

    Time frame: 10 min

Secondary outcomes

  1. Extended Dimensions of Climate Change Anxiety

    Subdimension scores from the extended version of the CCAS-FR, assessing cognitive, emotional, and functional disturbances, as well as direct or indirect experience of climate change and pro-environmental behaviors.

    Time frame: 10 min

  2. State and Trait Anxiety Scores

    Anxiety levels measured using the State-Trait Anxiety Inventory (STAI). The STAI-C is used for participants aged 16-17 years, and the STAI-Y for those aged 18-24 years. Separate state and trait anxiety scores will be analyzed Score ranges 20 to 80

    Time frame: 20 min

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07305688
Lead sponsor
Centre Hospitalier Esquirol
Responsible party
Bertrand Olliac (Professor, Centre Hospitalier Esquirol) — Principal investigator
First posted
Dec 26, 2025
Start date
Dec 15, 2025
Primary completion
Mar 15, 2027 (estimated)
Completion
Mar 15, 2027 (estimated)
Last update
Jun 4, 2026

Study contacts

Mireille BELLE MBOU, PhD
Contact
mireille.bellembou@ch-esquirol-limoges.fr
0587509130
Florence BOSSELUT, PhD
Contact
florence.bosselut@ch-esquirol-limoges.fr
Bertrand OLLIAC, MD, PhD
study director · Hospital Esquirol Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion